Articles Vol. 67 No. 1 15/01/2026

TREATMENT OUTCOMES OF CONCURRENT CHEMORADIOTHERAPY USING IMRT IN PATIENTS WITH STAGE III AND IVA-B HYPOPHARYNGEAL AND LARYNGEAL CANCER AT HANOI ONCOLOGY HOSPITAL

Pham Thi Thanh1,2, Phan Anh3,4, Tran Thi Kim Phuong1,2
1 University of Medicine and Pharmacy, Thai Nguyen University
2 Trường Đại học Y Dược, Đại học Thái Nguyên
3 Ha Noi Oncology Hospital
4 Bệnh viện Ung bướu Hà Nội
Corresponding author: bsthanhdhy@gmail.com
DOI: 10.52163/yhc.v67i1.4102
19 Views
12 Downloads
Keywords
Concurrent chemoradiotherapy, hypopharyngeal and laryngeal cancer, response rate.
Abstract

Objective: To describe several clinical characteristics and evaluate the treatment response in stage III and IVA-B hypopharyngeal and laryngeal cancer patients treated with concurrent intensity modulated radiation therapy-based chemoradiotherapy with every three-weekly Cisplatin at Hanoi Oncology Hospital.

Subject and methods: A cross-sectional study on 56 patients undergoing definitive concurrent chemoradiotherapy with every three-weekly Cisplatin and intensity modulated radiation therapy with a total dose of 66-70 Gy at Ha Noi Oncology Hospital from January 2021 to June 2025.

Results: The mean age at diagnosis was 54,8 ± 5,9 years, with a predominance of male patients. The most common reasons for hospitlization were dysphagia and cervical lymphadenopathy. Most cases were diagnosed at stage IVA-B (73.2%). The overall response rate was 96.4%, in which complete response rate was 50% and partial response was 46.4%. Lung metastasis occurred in 3.6% of patients after treatment. The disease stage had a significant association with the treatment response rate.

Conclusion: Concurrent intensity modulated radiation therapy-based chemoradiotherapy with every three-weekly Cisplatin for stage III and IVA-B hypopharyngeal-laryngeal cancer at Hanoi Oncology Hospital yielded favorable outcomes with a high treatment response rate.

References
[1]
Bray F, Laversanne M, Sung H, Ferlay J, Siegel Google Scholar
[2]
R.L, Soerjomataram I et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74 (3): 229-63. https://doi.org/10.3322/caac.21834. Google Scholar
[3]
Pignon J.P, le Maître A, Maillard E et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol, 2009, 92 (1): 4-14. Google Scholar
[4]
Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V et al. Weekly low-dose versus three-weekly high-dose Cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: A systematic review and meta-analysis of aggregate Google Scholar
[5]
data. Oncologist, 2017, 22 (9): 1056-66. Google Scholar
[6]
Chen Y.Y, Tsai Y.T, Tsai M.S, Hsu C.M, Lai C.H, Lu Google Scholar
[7]
C.H, et al. Treatment outcomes of locally advanced hypopharyngeal squamous cell carcinoma. Therapeutic Radiology and Oncology, 2018, 17 (2): 1-11. Google Scholar
[8]
Nguyễn Văn Công, Nguyễn Hải Hoàng, Võ Văn Xuân. Kết quả xạ trị điều biến liều kết hợp đồng thời Cisplatin bệnh ung thư hạ họng giai đoạn IIIIVA-BB tại Bệnh viện Ung bướu Nghệ An. Tạp chí Y Dược lâm sàng 108, 2023, 18 (số đặc biệt Hội nghị khoa học Xạ trị ung thư năm 2023): 206-212. Google Scholar
[9]
https://doi.org/10.52389/ydls.v18i0.1795. Google Scholar
[10]
Trần Hoàng Cường, Trần Viết Đức, Nguyễn Ngọc Sáng, Dương Thùy Linh, Bùi Quang Biểu. Đánh giá hiệu quả hóa xạ trị đồng thời triệt căn ung thư hạ họng thanh quản giai đoạn III, IVA-BA-B với Cisplatin chu kỳ 3 tuần. Tạp chí Y học Việt Nam, 2023, 2: 280-284. https://doi.org/10.51298/vmj. Google Scholar
[11]
v525i2.5244. Google Scholar
[12]
Krstevska V, Stojkovski I, Lukarski D. Concurrent radiochemotherapy in advanced hypopharyngeal cancer. Radiat Oncol, 2010, 18, 5: 39. https://doi. org/10.1186/1748-717X-5-39. Google Scholar
[13]
Noronha V, Joshi A, Patil V.M, Agarwal J, Ghosh-Laskar S, Budrukkar A et al. Once-a-week versus once-every-3-weeks Cisplatin chemoradiation for locally advanced head and neck cancer: A phase III randomized noninferiority trial. J Clin Oncol, 2018, 36 (11): 1064-72. https://doi.org/10.1200/jco.2017.74.9457. Google Scholar